Abstract:OBJECTIVE:Aplastic anemia is characterized by bone marrow failure and marked reduction of white blood cells, red blood cells and platelets in peripheral blood. Clinical studies have shown that immunosuppressive therapy greatly prolonged the long-term survival of some patients with aplastic anemia. But in severe aplastic anemia (SAA) patients whose ANC was < 0.5 x 10(9)/L, platelets were < 20 x 10(9)/L, very low bone marrow proliferation and high death rate were observed. The present study aimed to evaluate the efficacy of immunosuppressive treatments with cyclosporine A (CSA) alone or CSA combined with antithymocyte globin (ATG) in children with acquired SAA. METHODS:Fifty-four cases with SAA were treated with immunosuppressive agents mentioned above in our department from Jan. 1997 to June 2003, 31 of the cases had treated with CSA combined with ATG. There were 18 cases with SAA type I and 13 cases with SAA type II in CSA combined with ATG group, and 13 cases had very severe aplastic anemia. The other 23 cases were treated with CSA alone (CSA group), 10 of these cases had SAA-I and 13 had SAA-II, and 5 cases had very severe aplastic anemia. The responsive rate, relapse, adverse reactions and event free survival (EFS) were compared between CSA combined with ATG group and CSA group. RESULTS:The proportions of patients with different types of the disease and severity were comparable between the two groups. The responsive time of the CSA combined with ATG group and CSA group was 2.5 months and 3.5 months, respectively (P < 0.05), the responsive rate in two groups was 81% (25/31) and 52% (12/23), respectively (chi(2) = 4.962, P < 0.05). In 37 cases who were responsive to therapy, the relapse rate was 8% (2/25) and 50% (6/12) respectively (chi(C)(2) = 6.143, P < 0.05). There were no significant differences in adverse reactions to the immunosuppressive agents. All cases were followed-up for more than 1 year, and the event-free survival over one year in these two groups was 81% (25/31) and 52% (12/23), respectively. Forty-seven cases were followed-up for more than two years, and the event-free survival was 74% (20/27) and 50% (10/20), respectively (P < 0.01). Twelve cases were followed-up for over 5 years. There were no secondary tumor, myelodysplastic syndrome and other colony diseases. CONCLUSION:The immunosuppressive therapies for acquired severe aplastic anemia in childhood were effective. The effect of CSA combined with ATG was better than that of CSA alone, and the relapse rate was lower with the combined treatment. However, the long-term effect needs longer follow-up studies to evaluate.

The Benefit Of Atg In Immunosuppressive Therapy Of Children With Moderate Aplastic Anemia

Efficacy of antithymocyte-globulin in treatment of children with moderate aplastic anemia

Effectiveness of Immunosuppressive Therapy for Childhood Aplastic Anemia and Its Predictive Factors

[Treatment of Childhood Aplastic Anemia with Antithymocyte Globulin, Management of Side Effects and Long-Term Follow-Up].

Effect of Antithymocyte Globulin Source on Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia

[Efficacy of immunosuppressive therapy in children with acquired aplastic anemia]

Influential factors of response to childhood aplastic anemia treated with antithymocyte globulin and Cyclosporin A

[Immunosuppressive therapy for 54 children patients with acquired severe aplastic anemia].

Rabbit-antithymocyte Globulin Combined with Cyclosporin A As a First-Line Therapy: Improved, Effective, and Safe for Children with Acquired Severe Aplastic Anemia

Evaluation on the therapeutic efficacy of the combined immunosuppression therapy in children with aplastic anemia

Natural history of moderate aplastic anemia in children and effects of immunosuppresstve therapy

Analysis of the curative effect and its correlation factors of ALG as a Main Regimen of Immuno-suppressive Therapy in Treatment of Children Severe Aplastic Anemia

Efficacy and Safety of Combined Immunosuppressive Therapy Plus Umbilical Cord Blood Infusion in Severe Aplastic Anemia Patients: A Cohort Study

Therapeutic efficacy evaluation of rabbit anti-thymocyte globulin combined with cyclosporine A in children with aplastic anemia]

Clinical analysis of immunosuppressive therapy in childhood aplastic anemia

Treatment outcomes of 125 children with aplastic anemia.

A long-term follow up study on 345 severe aplastic anemia patients treated with antithymocyte globulin/lymphoglobulin

Evaluation of the efficacy of immunosuppressive treatments with antithymocyteglobin combined with cyclosporine A(CSA) in children with acquired very severe aplastic anemia

Immunosuppressive Therapy Versus Haploidentical Transplantation in Adults with Acquired Severe Aplastic Anemia.

Atg-Fresenius S Combined with Cyclosporine A: an Effective Immunosuppressive Therapy for Children with Aplastic Anemia

Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study